The American Cancer Society says more people will be diagnosed with cancer this year than ever before. Conventional treatments like surgery, chemotherapy, and radiation are helping to prevent deaths, but can more be done? Emerging research focused on repurposed drugs is proving the answer is YES.

The FLCCC Alliance is proud to announce it has partnered with renowned breast cancer physician and researcher Kathleen Ruddy, MD, to conduct an observational study in collaboration with five U.S. clinics to track patient responses to various adjunct cancer therapies using repurposed drugs. The aim is to determine changes in the five-year survival rate of several types of cancer including breast, prostate, lung, and colorectal.

FLCCC observational cancer study announcement

Study Details

FLCCC Cancer Study Announcement

Dr. Marik announces the cancer study partnership with Dr. Ruddy at the Winter 2024 FLCCC Educational Conference.

The final study results will focus on changes in the five-year survival rate of certain cancers and include patients from five clinics nationwide that will collaborate and share de-identified patient information in a protected data collection tool where the data will be tracked and analyzed.

Although the study uses the five-year survival rate after diagnosis as an endpoint, periodic updates of preliminary results will be provided while the study progresses.

The FLCCC Alliance published its Cancer Care Monograph in June 2023. In the FLCCC research partnership with Dr. Ruddy, we hope to build on the already promising results she has documented. It is our mission to bring safe, affordable, and effective cancer treatments to the patients who so desperately need them.

How It Will Work

During the study, participating clinics will collaborate and share de-identified patient information in a protected data collection tool where the data will be tracked and analyzed.

To assist with treatment and data collection, FLCCC has partnered with five clinics operating across the United States. Each clinic participating in the study will work to collaborate with their patients’ respective cancer treatment teams to ensure treatment conforms to patients’ wishes and does not conflict with other treatments. Each patient is responsible for the cost of their participation in the study.

“We hope that our research will bring attention to often overlooked methods for treating cancer as well as managing the symptoms from conventional treatment,” said Paul E. Marik, MD, FCCM, FCCP, lead author of the study, chief scientific officer of the FLCCC and former Chief of Pulmonary and Critical Care Medicine at Eastern Virginia Medical School.

Dr. Ruddy and Dr. Marik will act as lead investigators with Dr. Pierre Kory acting as contributing author. Patients interested in participating in the study should contact these clinics following their contact links listed in the following section below.

Dr. Kathleen Ruddy

Founder, Health and Healing
Lead Investigator, FLCCC Cancer Study

Dr. Paul Marik

Chief Scientific Officer, FLCCC
Lead Investigator, FLCCC Cancer Study